A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturers responsible for batch release
Swords Laboratories T/A Lawrence Laboratories, Unit 12, The Distribution Centre, Shannon Industrial Estate, Shannon, Co. Clare, Ireland
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
- Irbesartan hydrochlorothiazide bms - Bristol-Myers Squibb Pharma EEIG
- Zerit - Bristol-Myers Squibb Pharma EEIG
- Clopidogrel bms - Bristol-Myers Squibb Pharma EEIG
- Evotaz - Bristol-Myers Squibb Pharma EEIG
- Baraclude - Bristol-Myers Squibb Pharma EEIG
- Sustiva - Bristol-Myers Squibb Pharma EEIG
Prescription drugs listed. Manufacturer: "Bristol-Myers Squibb Pharma EEIG"
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
- Atazanavir mylan - J05AE08
Prescription drugs listed. ATC Code: "J05AE08"
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Risk Management plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
At the request of the European Medicines Agency;
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.